TB-500 Legal Status, FDA 503A Category, and Compounding Access

Access is under active FDA review — here is the momentum, and the fact under it

The TB-500 legal status picture leads with momentum, not a closed door: the compounding access question for TB-500 is under active FDA review and may expand in 2026. That momentum is real and it is anchored to a single verifiable fact — "TB-500 (free base)" and "TB-500 acetate" are individually named on the published agenda of the FDA Pharmacy Compounding Advisory Committee (PCAC) meeting scheduled for July 23–24, 2026, as bulk drug substances "being considered for inclusion on the 503A Bulks List" ^[20]. The same agenda also lists BPC-157, KPV, and MOTS-c ^[20].

Read that precisely. A scheduled PCAC discussion is a step in evaluation — it is not a listing decision, not a reclassification, and not a change in current status ^[20]. Inclusion on a final 503A bulks list is decided by FDA rulemaking informed by the committee; being discussed by the committee is evaluation, not a final listing ^[19]. No outcome of the July 2026 meeting should be assumed or dated ^[20]. This page states the present-tense, FDA-citable facts and frames the future strictly as a scheduled discussion.

Is TB-500 FDA Approved?

No. TB-500 is not an FDA-approved drug, and it has no approved therapeutic indication ^[18]. FDA approval of a finished drug (a New Drug Application or Biologics License Application) is a separate question from whether a bulk substance may be used in compounding, and TB-500 has neither — it is not approved, and its compounding-ingredient status is the Category 2 standing described below ^[19]. The current fact: the FDA — which lists the entry as "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" — placed it in 503A "Category 2" (bulk substances that may present significant safety risks), effective with the FDA's September 29, 2023 nominated-substances update, citing concerns including potential immunogenicity for certain routes of administration and a lack of important safety information ^[18]. As a Category 2 substance it is NOT within the FDA's enforcement-discretion policy for 503A compounding ^[18].

What FDA 503A "Category 2" actually means

Drug compounding in the U.S. is governed by two sections of the Federal Food, Drug, and Cosmetic Act. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies and physicians pursuant to a valid prescription; Section 503B covers FDA-registered "outsourcing facilities" that compound larger batches under cGMP-style oversight ^[19]. A compounder may use a bulk drug substance only if it has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on the relevant FDA bulks list; otherwise the substance is evaluated by the FDA through a public nomination process with input from the PCAC ^[19].

Under the FDA's interim policy, Category 2 substances are those nominated with enough information to evaluate but identified as raising significant safety risks — and they are NOT covered by the enforcement-discretion policy that applies to Category 1 ^[19]. The FDA stated it would consider taking action against a compounder for compounding with a Category 2 substance ^[19]. On January 7, 2025, the FDA finalized a revised interim policy under which it no longer sorts newly nominated substances into these numbered categories; substances already in Category 2 are not afforded enforcement discretion even if nominations are updated ^[19]. TB-500's Category 2 standing is the last FDA action confirmable from FDA.gov.

How legally compounded peptide access works (in general)

In general terms — not as instructions for any individual — a legally compounded medication in the U.S. is prepared only after a licensed prescriber evaluates an individual patient, determines a compounded preparation is appropriate, and issues a valid, patient-specific prescription ^[19]. The preparation is then made by a state-licensed 503A compounding pharmacy (patient-specific) or, for larger or office-use volumes, sourced from an FDA-registered 503B outsourcing facility ^[19]. Telehealth can serve as the front-end channel through which a patient is evaluated and a prescription is issued, but it does not change which substances are eligible to be compounded and does not remove the need for a legitimate prescriber-patient relationship and a valid prescription ^[19].

The ingredient-eligibility caveat is the binding constraint here: a compounder may use a requested active ingredient only if that ingredient is eligible under the 503A/503B bulk-substance rules, and an ingredient the FDA has flagged for significant safety risks — a Category 2 substance such as TB-500 — is not eligible for routine 503A compounding while that status stands ^[19]. This page does not name any pharmacy, clinic, telehealth provider, or vendor, provides no dosing, and describes no way to obtain any substance outside the lawful framework.

Is TB-500 banned by WADA and in competitive sports?

Yes. TB-500 (and thymosin beta-4) fall under the World Anti-Doping Agency's prohibited peptide, growth-factor and tissue-repair categories, and are banned both in and out of competition for the relevant classes ^[6]. The substance has been encountered as a designer drug in racehorses, which prompted equine and human anti-doping detection methods; LC-MS assays detect TB-500 and its metabolites in equine and human matrices ^[6][17]. The fragment's precise chemical identity was published specifically as a doping-control reference ^[17].

A note on unconfirmed reclassification reports

Some commercial and clinic sources have reported that in early 2026 a portion of the peptides placed in Category 2 in 2023 were expected to move back toward Category 1, and some pages assert specific dates on which substances were "removed" from Category 2. As of the verification date of the source used for this page, those reports could not be confirmed as completed, effective FDA actions from an authoritative FDA source, and the most candid of them note the FDA had not published a formal updated list and that the matter was still pending. This page does not present any reclassification as having occurred. The current, FDA-citable status remains Category 2, and the July 2026 PCAC agenda still listing TB-500 as a candidate is consistent with its evaluation being ongoing rather than resolved ^[20].

This page is general information about the regulatory landscape. It is not medical or legal advice, and it is not an offer to sell or supply any substance.